Key facts
- Ace Vision’s last known valuation is $114.1M (Jan 2022).
- It has raised $79.2M; the latest was Later Stage VC ($29.4M) in Apr 2025.
- Notable investors include Poalim Equity, Robert Picerne, Santen, Sneci, The Picerne Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Ace Vision
- ·The full record, as it builds
Funding rounds
No funding rounds for Ace Vision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ace Vision
Developer of an eye laser technology designed to treat vision loss, prevent and restore the aging eye. The company's technology offers a laser-based therapeutic for vision loss prevention and restoration of the aging eye, enabling surgeons to restore natural visual accommodation for clear near, intermediate, and distance vision.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2006
- Employees
- 21
- Website
- acevisiongroup.com/
- Ownership
- Privately Held (backing)
Ace Vision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ace Vision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ace Vision in its N-PORT filings yet. We sweep new filings monthly.